Companies · Other Health Care

Metabolon, Inc

DURHAM · Other Health Care

Diligence memoA one-page analyst read on Metabolon, Inc — recommendation, valuation, rhythm, risks.
$123.6M
Total raised · real
10
Rounds
0.7×
Latest step-up
Top 4%
Sector rank · raised
Series B
Latest stage · inferred · Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Metabolon, Inc looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.28× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
Quiet
  • Last raise 18 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Metabolon, Inc is one of 5377 Other Health Care companies tracked from DURHAM. By capital raised it ranks among the largest (ahead of 97% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
11
Investors (latest)
2024-12-31
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2008-04-30 Raised $5.3M (real) Modeled valuation $106M (est)Series A2008Series A · 2009-04-30 Raised $6.3M (real) Modeled valuation $127M (est)Series A2009Series A · 2009-10-22 Raised $6.1M (real) Modeled valuation $123M (est)Series A2009Series A · 2011-08-25 Raised $13M (real) Modeled valuation $265M (est)Series A2011Series A · 2013-12-16 Raised $15M (real) Modeled valuation $303M (est)Series A2013Series A · 2015-03-02 Raised $5.0M (real) Modeled valuation $102M (est)Series A2015Series B · 2016-08-10 Raised $30M (real) Modeled valuation $665M (est)Series B2016Series A · 2016-08-10 Raised $15M (real) Modeled valuation $303M (est)Series A2016Series B · 2018-08-15 Raised $7.3M (real) Modeled valuation $162M (est)Series B2018Series B · 2019-08-13 Raised $7.8M (real) Modeled valuation $172M (est)Series B2019Seed · 2019-08-13 Raised $1.5M (real) Modeled valuation $37M (est)Seed2019Series B · 2020-08-28 Raised $22M (real) Modeled valuation $460M (est)Series B2020Series B · 2022-11-01 Raised $10M (real) Modeled valuation $109M (est)Series B2022Series B · 2024-12-31 Raised $7.5M (real) Modeled valuation $42M (est)Series B2024Cumulative $152M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.3M · 2008
Series A extension$6.3M · 2009
Series A extension$6.1M · 2009
Series A extension$13.2M · 2011
Series A extension$15.0M · 2013
Series A extension$5.0M · 2015
Series B$30.0M · 2016
Bridge · Series B-stage$15.0M · 2016smaller follow-on
Series B extension$7.3M · 2018
Series B extension$7.8M · 2019
Bridge · Series B-stage$1.5M · 2019smaller follow-on
Series B extension$21.8M · 2020
Series B extension$10.0M · 2022
Series B extension$7.5M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$42.1M
Base estimate est.
$17.6M
Conservative case
$68.5M
Upside case
$41.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $106.4M · 2008-04-302008Series A · modeled $126.6M · 2009-04-30Series A · modeled $122.6M · 2009-10-22Series A · modeled $265.5M · 2011-08-25Series A · modeled $302.7M · 2013-12-16Series A · modeled $101.9M · 2015-03-02Series B · modeled $664.6M · 2016-08-10Series A · modeled $302.7M · 2016-08-10Series B · modeled $161.7M · 2018-08-15Series B · modeled $171.7M · 2019-08-13Seed · modeled $37.2M · 2019-08-13Series B · modeled $459.6M · 2020-08-28Series B · modeled $109.2M · 2022-11-01Series B · modeled $42.1M · 2024-12-312024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
1.5 yr
Elapsed time used
1.5 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$7.4M/yr
Capital velocity
18.2 yr
On record since
2008
First round
14
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 51× above median
This company$123.6M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.4× of median
This company$7.5M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 1.9× above median
This company$42.1M
Sector median$22.1M

Raised more than 97% of sector peers (real $). Modeled value above 64% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #79 of 91.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Code Biotherapeutics, Inc. · Series B Raised $47.5M · modeled $465.8M (est)Candesant Biomedical, Inc. · Series B Raised $44.5M · modeled $455.3M (est)Artis Holdings, LLC · Series B Raised $40.0M · modeled $383.5M (est)GIO Blood Ltd · Series B Raised $27.3M · modeled $375.5M (est)Clarapath, Inc. · Series B Raised $40.2M · modeled $348.4M (est)Diality Inc · Series B Raised $42.9M · modeled $337.7M (est)VA Pro 7 SNF Operations Holdings LLC · Series B Raised $32.0M · modeled $333.3M (est)VivoSense, Inc. · Series B Raised $27.0M · modeled $332.6M (est)Tidal Wave GPO, LLC · Series B Raised $34.8M · modeled $324.6M (est)Peachy Corp. · Series B Raised $25.1M · modeled $309.9M (est)Smile Source Holdings, L.P. · Series B Raised $32.2M · modeled $309.0M (est)ASC San Rafael LLC · Series B Raised $28.3M · modeled $295.1M (est)Metabolon, Inc (this company) Raised $123.6M · modeled $42.1M (est)Metabolon, Inc
CompanyStageRaised · realValue · estvs peer med.
Code Biotherapeutics, Inc.Series B$47.5M$465.8M3.06×
Candesant Biomedical, Inc.Series B$44.5M$455.3M2.99×
Artis Holdings, LLCSeries B$40.0M$383.5M2.52×
GIO Blood LtdSeries B$27.3M$375.5M2.47×
Clarapath, Inc.Series B$40.2M$348.4M2.29×
Diality IncSeries B$42.9M$337.7M2.22×
VA Pro 7 SNF Operations Holdings LLCSeries B$32.0M$333.3M2.19×
VivoSense, Inc.Series B$27.0M$332.6M2.19×
Tidal Wave GPO, LLCSeries B$34.8M$324.6M2.13×
Peachy Corp.Series B$25.1M$309.9M2.04×
Smile Source Holdings, L.P.Series B$32.2M$309.0M2.03×
ASC San Rafael LLCSeries B$28.3M$295.1M1.94×
Metabolon, Inc this companySeries B$123.6M$42.1M0.28×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.3M2008-04-30$24.0M$106.4M85%
Series A$6.3M2009-04-30$28.5M$126.6M85%
Series A$6.1M2009-10-22$27.6M$122.6M85%
Series A$13.2M2011-08-25$59.8M$265.5M85%
Series A$15.0M2013-12-16$68.2M$302.7M85%
Series A$5.0M2015-03-02$23.0M$101.9M85%
Series B$30.0M2016-08-10$166.7M$664.6M90%
Series A$15.0M2016-08-10$68.2M$302.7M85%
Series B$7.3M2018-08-15$40.6M$161.7M90%
Series B$7.8M2019-08-13$43.1M$171.7M90%
Seed$1.5M2019-08-13$7.5M$37.2M90%
Series B$21.8M2020-08-28$120.9M$459.6M90%
Series B$10.0M2022-11-01$55.8M$109.2M90%
Series B$7.5M2024-12-31$41.7M$42.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.3M2008-04-30
    • First recorded raise — entered as Series A.
    • 5 investors on this round.
  2. Series A$6.3M2009-04-30
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
  3. Series A$6.1M2009-10-22
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 5 investors on this round.
  4. Series A$13.2M2011-08-25
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 12 investors on this round.
  5. Series A$15.0M2013-12-16
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 15 investors on this round.
  6. Series A$5.0M2015-03-02
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  7. Series B$30.0M2016-08-10
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 5.9× larger than the prior — scaling up.
    • 2 investors on this round.
  8. Series A$15.0M2016-08-10
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  9. Series B$7.3M2018-08-15
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  10. Series B$7.8M2019-08-13
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 11 investors on this round.
  11. Seed$1.5M2019-08-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.2× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  12. Series B$21.8M2020-08-28
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 14.5× larger than the prior — scaling up.
    • 11 investors on this round.
  13. Series B$10.0M2022-11-01
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
    • 11 investors on this round.
  14. Series B$7.5M2024-12-31
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 11 investors on this round.
Intelligence
2026 ~Q2
Modeled next raise · ~15mo cadence
$7.5M
Modeled next size est.range $7.5M$12.0M
0.7×
Last step-up
$7.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
B. Jefferson Clark11 other2015-03
John Oxaal6 other2008-04
David Pierson4 other2019-08
Edward L. Erickson3 other2008-04
R. John Fletcher3 other2019-08
R. Scott Barry2 other2019-08
Christopher J. Kersey1 other2015-03
John A. Oxaal1 other2015-03
Carol A. Marino2009-10
C Thomas Caskey2008-04
David John Pierson2019-08
David Thomas Pierson2016-08
Edward L. Erikson2009-10
Gerald M. Haines II2024-12
Guy A. Fish2009-10
Guy B. Fish2011-08
Guy Thomas Fish2015-03
Jan Jefferson Lundberg2019-08
Jan John Lundberg2020-08
Jan Lundberg2019-08
Jefferson B Clark2008-04
John A Ryals2008-04
John B. Oxaal2009-10
John F. Kurtzweil2020-08
Registry & provenance

Metabolon, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1223710
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Mri Interventions, Inc.Other Health CareSeries B$90.0M$76.6Mnetwork1 shared operator · same sector · same stage
Airwavz Solutions, Inc.Other TechnologySeries B$53.1M$328.0Mnetwork2 shared operators · same stage
Specialists On Call, Inc.Other Health CareSeries B$131.7M$44.3Msame sector · same stage
OptiNose, Inc.PharmaceuticalsSeries B$120.4M$34.7Mnetwork1 shared operator · same stage
Regado Biosciences IncBiotechnologySeries B$141.7M$793.8Mnetwork1 shared operator · same stage
Luxtera IncOther TechnologySeries B$91.8M$1.1Bnetwork1 shared operator · same stage
Veritas Collaborative Holdings, LLCOther Health CareSeries A$32.4M$46.3Mnetwork1 shared operator · same sector
Javara Inc.Other Health CareSeries B$59.7M$33.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Restor Metabolix IncOther Health CareSeed$9.3M87%
MetaModix, Inc.Other Health CareSeed$4.2M87%
MetaCan, Inc.Other Health CareSeries A$5.9M86%
FloSpine Holdings, Inc.Other Health CarePre-Seed$409K85%
Cardionomic, Inc.Other Health CareSeries B$76.3M85%
Kalogon, Inc.Other Health CareSeed$5.8M84%
Biolase, IncOther Health CareSeries A$16.1M84%
Thrombolex, Inc.Other Health CareSeries B$129.3M83%
Frequently asked
How much funding has Metabolon, Inc raised?
Metabolon, Inc has raised approximately $123.6M in disclosed capital across 10 recorded financing rounds, aggregated from public filings.
What is Metabolon, Inc's estimated valuation?
Provath's modeled valuation for Metabolon, Inc is approximately $42.1M (modeled range $17.6M–$68.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Metabolon, Inc at?
Metabolon, Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Dec 31.
What does Metabolon, Inc do and where is it based?
Metabolon, Inc operates in the Other Health Care sector, based in DURHAM.
Explore related

See where Metabolon, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Metabolon, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.